VEGFA and colorectal carcinoma: Although bevacizumab, an anti-VEGF monoclonal antibody, is effective in the overall population of CRC patients, the toxicities of bleeding, perforation and obstruction cannot be ignored, especially in patients with ulcerative primary lesions, who tend to have severe adverse reactions.